Cargando…

Vaccine Hesitancy in Patients With Multiple Sclerosis: Preparing for the SARS-CoV-2 Vaccination Challenge

OBJECTIVE: Vaccine hesitancy is a complex public health issue referring to concerns about safety, efficacy, or need for vaccination. Using pneumococcal vaccination, which is recommend in anti-CD20–treated multiple sclerosis (MS) patients, as a model, we assessed vaccination behavior in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diem, Lara, Friedli, Christoph, Chan, Andrew, Salmen, Anke, Hoepner, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018793/ https://www.ncbi.nlm.nih.gov/pubmed/33811158 http://dx.doi.org/10.1212/NXI.0000000000000991

Ejemplares similares

Multiple sclerosis as a model to investigate SARS‐CoV‐2 effect on brain atrophy
por: Rebsamen, Michael, et al.
Publicado: (2022)

Predicting conversion to multiple sclerosis in patients with radiologically isolated syndrome: a retrospective study
por: Chaloulos-Iakovidis, Panagiotis, et al.
Publicado: (2021)

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients
por: Hammer, Helly, et al.
Publicado: (2022)

Is COVID‐19 severity associated with reduction in T lymphocytes in anti‐CD20‐treated people with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?
por: Hoepner, Robert, et al.
Publicado: (2022)

Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies
por: Friedli, Christoph, et al.
Publicado: (2021)

Application of the “risk of ambulatory disability” (RoAD) score in a “real‐world” single‐center multiple sclerosis cohort
por: Pistor, Maximilian, et al.
Publicado: (2022)

Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age
por: Briner, Myriam, et al.
Publicado: (2019)

Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course
por: Zoehner, Greta, et al.
Publicado: (2019)

Pathological cerebrospinal fluid protein concentration and albumin quotient at relapse predicts short-term disability progression in multiple sclerosis: a retrospective single center observational study
por: Diem, Lara, et al.
Publicado: (2020)

Reliable brain morphometry from contrast‐enhanced T1w‐MRI in patients with multiple sclerosis
por: Rebsamen, Michael, et al.
Publicado: (2022)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
por: Hoepner, Robert, et al.
Publicado: (2014)

Socioeconomic and Regional Disparities in Industry-Sponsored Clinical Trials in Multiple Sclerosis
por: Marti, Stefanie, et al.
Publicado: (2023)

Vaccine hesitancy in people with multiple sclerosis
por: Lechner-Scott, Jeannette S, et al.
Publicado: (2022)

Multidimensional phenotyping of the post‐COVID‐19 syndrome: A Swiss survey study
por: Diem, Lara, et al.
Publicado: (2022)

Vaccine hesitancy among people with multiple sclerosis
por: Yap, Siew Mei, et al.
Publicado: (2021)

Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System
por: Pistor, Maximilian, et al.
Publicado: (2022)

The impact of immunotherapies on COVID-19 case fatality rates during the US vaccination campaign: a multidisciplinary open data analysis using FDA Adverse Event Reporting System and Our World in Data
por: Salmen, Anke, et al.
Publicado: (2023)

Age‐dependent variation of female preponderance across different phenotypes of multiple sclerosis: A retrospective cross‐sectional study
por: Miclea, Andrei, et al.
Publicado: (2018)

An algorithm using clinical data to predict the optimal individual glucocorticoid dosage to treat multiple sclerosis relapses
por: Gili-Kovács, Judit, et al.
Publicado: (2021)

Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus
por: Mok, Chi Chiu, et al.
Publicado: (2022)

COVID-19 vaccine hesitancy in Iranian patients with multiple sclerosis
por: Abbasi, Naghmeh, et al.
Publicado: (2022)

Fatigue in Post-COVID-19 Syndrome: Clinical Phenomenology, Comorbidities and Association With Initial Course of COVID-19
por: Diem, Lara, et al.
Publicado: (2022)

Vaccine Hesitancy: Obstacles and Challenges
por: Galagali, Preeti M., et al.
Publicado: (2022)

Vaccine hesitancy for coronavirus SARS-CoV-2 in Varanasi India
por: Srivastava, Utkarsh, et al.
Publicado: (2022)

COVID-19 vaccine hesitancy among Italian people with multiple sclerosis
por: Proietti, Francesca, et al.
Publicado: (2022)

Evaluation of diagnostic criteria and red flags of myelin oligodendrocyte glycoprotein encephalomyelitis in a clinical routine cohort
por: Veselaj, Krenar, et al.
Publicado: (2020)

Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
por: Woopen, Christina, et al.
Publicado: (2021)

1172. SARS-CoV-2 Vaccine Hesitancy in Caregivers of Hospitalized Children
por: Orbea, Marisa, et al.
Publicado: (2021)

Vaccine hesitancy promotes emergence of new SARS-CoV-2 variants
por: Jing, Shuanglin, et al.
Publicado: (2023)

Prediction of conversion to multiple sclerosis using the 2017 McDonald and 2016 MAGNIMS criteria in patients with clinically isolated syndrome: a retrospective single-centre study
por: Miclea, Andrei, et al.
Publicado: (2019)

Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study
por: Ziello, Antonio, et al.
Publicado: (2021)

Experiences of persons with multiple sclerosis with the Covid-19 vaccination: A cross-sectional study of the Swiss Multiple Sclerosis Registry
por: Stanikić, Mina, et al.
Publicado: (2023)

Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination
por: Faissner, Simon, et al.
Publicado: (2022)

Sars-CoV2 vaccine hesitancy in Italy: A survey on subjects with diabetes
por: Scoccimarro, Daniele, et al.
Publicado: (2021)

SARS-CoV-2 Vaccination in India: Considerations of Hesitancy and Bioethics in Global Health
por: Sarkar, Mohammad Abdullah, et al.
Publicado: (2021)

Studying SARS-CoV-2 vaccine hesitancy among health professionals in Tunisia
por: Zammit, Nawel, et al.
Publicado: (2022)

The SARS-CoV-2 vaccination rate and hesitation in Shanghai older adults with dementia
por: Yang, Yang, et al.
Publicado: (2023)

Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
por: Sellner, Johann, et al.
Publicado: (2021)

SARS-CoV-2 vaccines tolerability: A perspective by people with multiple sclerosis
por: Di Filippo, Massimiliano, et al.
Publicado: (2022)

Vaccine hesitancy with a history of Guillain Barre Syndrome: Weighing the risks and benefits of SARS-CoV-2 vaccination()
por: Murawska Baptista, Aleksandra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cafm93onaq0hi1rt176inl4t4c